Back Ipsen Group German Ipsen Spanish ایپسن Persian Ipsen French Ipsen ID Ipsen Italian イプセン (製薬会社) Japanese Ipsen Malay Ipsen Portuguese Ipsen Russian

Ipsen

This article is about the company. For a list of people with the surname, see Ipsen (surname).

Ipsen
Company typePublic
Euronext Paris: IPN
CAC Mid 60 Component
ISINFR0010259150
IndustryPharmaceutical
Founded1929
FounderHenri Beaufour
HeadquartersBoulogne-Billancourt, France
Key people
Marc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
ProductsList of medicines
RevenueIncrease €3.128 billion(2023)[1]
Increase €1.001 billion(2023)[1]
Increase €647 million(2023)[1]
Number of employees
5,700[1]
Websitewww.ipsen.com
Footnotes / references
[1]

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.[2][3]

Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005).[4][5] The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.[6]

  1. ^ a b c d e "FY 2023 results" (PDF). Ipsen.
  2. ^ "Ipsen: A dynamic, fast-growing specialty care powerhouse".
  3. ^ "Ipsen | Evaluate".
  4. ^ "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 13 December 2022.
  5. ^ "Ipsen, le défi américain". Les Echos (in French). 1 October 2015. Retrieved 13 December 2022.
  6. ^ France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". www.lechorepublicain.fr. Retrieved 13 December 2022.

Developed by StudentB